P.F. CHANG
B.Eng (Bioengineering), Chartered Engineer, CEng (UK)
Cofounder & CEO
Mr Chang holds a Bachelor of Engineering degree with a Major in Bioengineering from Nanyang Technological University (NTU) in Singapore. In 2010, he established his first agrobiotech company to produce and supply biotech-derived therapeutic materials to healthcare corporations in Singapore. In 2012, he formulated and secured CPM approval from the Health Sciences Authority (HSA) of Singapore for the first High Active Ingredient Certified-Organic Cordyceps capsule product and trademarked in Singapore (2012). He further developed advanced Analytical and Quality Control Systems to optimize and ensure consistency in pharmacologically active substances.
In 2015, Mr Chang became a qualified Member of the Asia Regulatory Professional Association (ARPA) in Singapore. By 2022, he was accepted as a Member of the Institution of Engineering and Technology (MIET) and was awarded the Chartered Engineer (CEng) designation by the Engineering Council in the United Kingdom. He currently serves as the Chief Executive Officer (CEO) of SINOAGRO GROUP.
Mr Chang also pioneered the SINGAPORE SCIENCES Clinical Studies & Advanced Development (CSAD) programme, through which a series of novel translational medicine products were developed, applied in the field of diabetes, organ ageing, chemoprevention, and inflammatory-associated medical conditions (Grant of Patent/Trademark 2015 & 2018 & 2022, Singapore). The completion of its findings were accepted and published in the peer-reviewed Journal of Complementary Medicine & Alternative Healthcare (JCMAH) in USA. The Health Sciences Authority of Singapore (HSA) has granted its approval and is commercially available in Singapore.
Under the tutelage of Professor Patrick H.M. Loh and together with his team at SINGAPORE SCIENCES, Mr Chang’s cumulated experience has laid the foundation for the development of novel healthcare products in Singapore.
Mr P.F. Chang
B.Eng (Bioengineering), Chartered Engineer, CEng (UK)
Cofounder & CEO
Mr P.F. Chang graduated with a Bachelor of Engineering, Major in Bioengineering from the Nanyang Technological University (NTU) in Singapore. Whilst reading for his Bachelor’s degree, he was one of the few undergraduates selected to join the Bioengineered & Applied Nanomaterials Laboratory in NTU to undertake drug formulation/delivery project pertaining to the investigation of ‘Protein Nanocages’.
In 2010, his breakthrough innovation in the nurturing of precious medicinal plants under controlled-environment was realised in Singapore. This discovery led to the scale-up development for achieving the most potent medicinal plant known in the market with compliance to the Health Sciences Authority (HSA) of Singapore’s Safety Standards. He went further to successfully developed Analytical and Quality Control Systems to optimise and quantify the consistency of active ingredients from the batches of raw medicinal plants nurtured at the production facilities.
In 2010, he established his first agrobiotech company to produce and supply authenticated herbal materials to the Traditional Chinese Medicine (TCM) corporations and nutraceutical industries in Singapore. In 2012, he formulated and obtained the necessary Chinese Proprietary Medicine (CPM) approval from the Health Sciences Authority (HSA) of Singapore for the first High Active Ingredient Certified-Organic Cordyceps capsule product (Grant of Patent/Trademark 2012, Singapore) in Singapore.
In 2015, Mr Chang becomes a qualified Member of the Asia Regulatory Professional Association (ARPA) in Singapore. In 2022, he was accepted as a Member of the Institution of Engineering and Technology (MIET) and has been awarded Chartered Engineer (CEng) by the Engineering Council in the United Kingdom. Mr Chang is also the Chief Executive Officer (CEO) of SINOAGRO GROUP.
Mr Chang also pioneered the SINGAPORE SCIENCES’ Clinical Studies & Advanced Development (CSAD) programme, through which a series of novel translational medicine products were developed, applied in the field of diabetes, organ ageing processes, chemoprevention, and inflammatory associated medical conditions (Grant of Patent/Trademark 2015 & 2018 & 2022, Singapore). The completion of its findings were accepted and published in the peer-reviewed Journal of Complementary Medicine & Alternative Healthcare (JCMAH) in USA. The Health Sciences Authority of Singapore (HSA) has granted its approval and is commercially available in Singapore.
Under the tutelage of Professor Patrick H.M. Loh and together with his team at SINGAPORE SCIENCES, Mr Chang’s cumulated experience has laid the foundation for the development of novel healthcare products in Singapore.
